Antinuclear Antibodies, HEp-2 Substrate, IgG, Serum

Mayo Clinic Laboratories test catalog entry for ANA by IFA on HEp-2 (NAIFA). Describes method, screening dilution, reportable nuclear/cytoplasmic/mitotic patterns, reference range, and interpretive cautions that positive anticellular antibody lacks diagnostic specificity. Candidate notes: Method is indirect immunofluorescence on HEp-2; specimens screened at 1:80. Reference value: <1:80 (Negative). Nuclear patterns reported with titers include centromere, homogeneous, nuclear dots, nucleolar, speckled, fine dense speckled (DFS70), and PCNA. Cytoplasmic patterns (e.g., AMA, cytoplasmic speckled, Golgi-like, rods and rings) and selected mitotic patterns are also reported if observed. Positive results require confirmation with specific associated antibody tests except for the highly characteristic centromere pattern. Negative results do not necessarily rule out systemic autoimmune rheumatic disease. Positive results may occur in healthy individuals and with infections, cancers, or certain medications. Limits noted in the record: Laboratory-specific assay and cutoffs; performance can vary by demographics and clinical context. A positive ANA is not a diagnosis. Claims in this record are not verified.

A positive ANA is not a diagnosis. Claims in this record are not verified.

source